Abstract:Abstract Background The positive transcription elongation factor b (P-TEFb) kinase activity is involved in the process of transcription. Cyclin-dependent kinase 9 (CDK9), a core component of P-TEFb, regulates the process of transcription elongation, which is associated with differentiation and apoptosis in many cancer types. Wogonin, a natural CDK9 inhibitor isolated from Scutellaria baicalensis. This study aimed to investigate the involved molecular mechanisms of wogonin on anti- chronic myeloid leukemia (CML) cells. Materials and methods mRNA and protein levels were analysed by RT-qPCR and western blot. Flow cytometry was used to assess cell differentiation and apoptosis. Cell transfection, immunofluorescence analysis and co-immunoprecipitation (co-IP) assays were applied to address the potential regulatory mechanism of wogonin. KU-812 cells xenograft NOD/SCID mice model was used to assess and verify the mechanism in vivo. Results We reported that the anti-CML effects in K562, KU-812 and primary CML cells induced by wogonin were regulated by P-TEFb complex. We also confirmed the relationship between CDK9 and erythroid differentiation via knockdown the expression of CDK9. For further study the mechanism of erythroid differentiation induced by wogonin, co-IP experiments were used to demonstrate that wogonin increased the binding between GATA-1 and FOG-1 but decreased the binding between GATA-1 and RUNX1, which were depended on P-TEFb. Also, wogonin induced apoptosis and decreased the mRNA and protein levels of MCL-1 in KU-812 cells, which is the downstream of P-TEFb. In vivo studies showed wogonin had good anti-tumor effects in KU-812 xenografts NOD/ SCID mice model and decreased the proportion of human CD45 + cells in spleens of mice. We also verified that wogonin exhibited anti-CML effects through modulating P-TEFb activity in vivo. Conclusions Our study indicated a special mechanism involving the regulation of P-TEFb kinase activity in CML cells, providing evidences for further application of wogonin in CML clinical treatment.

Wogonin As a Targeted Therapeutic Agent for EBV (+) Lymphoma Cells Involved in LMP1/NF-κB/Mir-155/PU.1 Pathway

Effect of Magnetic Nanoparticles on Apoptosis and Cell Cycle Induced by Wogonin in Raji Cells

Wogonin induces mitochondrial apoptosis and synergizes with venetoclax in diffuse large B-cell lymphoma

Wogonin, a Natural and Biologically-active Flavonoid, Influences a Murine WEHI-3 Leukemia Model in Vivo Through Enhancing Populations of T- and B-Cells

Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia

Wogonin Induced Calreticulin/Annexin A1 Exposure Dictates the Immunogenicity of Cancer Cells in A Perk/Akt Dependent Manner

Wogonin Induced Differentiation and G1 Phase Arrest of Human U-937 Leukemia Cells Via PKCdelta Phosphorylation.

Wogonin Suppresses IL-10 Production in B Cells Via STAT3 and ERK Signaling Pathway.

The Antitumor effect of wogonin, a lipoxygenase inhibitor, in both estrogen receptor-positive and -negative human breast cancers.

On the mechanism of wogonin against acute monocytic leukemia using network pharmacology and experimental validation

Wogonoside induces growth inhibition and cell cycle arrest via promoting the expression and binding activity of GATA-1 in chronic myelogenous leukemia cells

Wogonin Suppresses Tumor Growth in Vivo and VEGF-induced Angiogenesis Through Inhibiting Tyrosine Phosphorylation of VEGFR2.

Wogonin inhibits multiple myeloma-stimulated angiogenesis via c-Myc/VHL/HIF-1α signaling axis.

Advances of Wogonin, an Extract from Scutellaria Baicalensis, for the Treatment of Multiple Tumors

Wogonin Inhibits the Proliferation and Invasion, and Induces the Apoptosis of HepG2 and Bel7402 HCC Cells Through NF‑κB/Bcl-2, EGFR and EGFR Downstream ERK/AKT Signaling.

Wogonin Reverses Multi-Drug Resistance of Human Myelogenous Leukemia K562/A02 Cells Via Downregulation of MRP1 Expression by Inhibiting Nrf2/ARE Signaling Pathway.

Influence of Adriamycin and Wogonin on the Expression of Mir-155 in Burrkit Lymphoma in Vitro

Inhibitory Effects of Wogonin on the Invasion of Human Breast Carcinoma Cells by Downregulating the Expression and Activity of Matrix Metalloproteinase-9

[Recombinant Soluble CD40 Ligand Enhances Wogonin-induced Antitumor Activity].

Wogonin inhibits LPS-induced tumor angiogenesis via suppressing PI3K/Akt/NF-κB signaling

Main Signal Pathways Underlying the Molecular Mechanisms of the Antitumor Effects of Wogonin